Generic Pharma Co. Pushes Fed. Circ. To Revive Avanir IP Row
Par Pharmaceuticals Inc. on Friday called for a Federal Circuit panel to invalidate Avanir Pharmaceuticals Inc.'s patent on neurological drug Neudexta, telling the judges the trial court ignored that prior art...To view the full article, register now.
Already a subscriber? Click here to view full article